Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.

Guardado en:
Detalles Bibliográficos
Autores principales: Mencinger Marina, Mangaroski Dusan, Bokal Urska
Formato: article
Lenguaje:EN
Publicado: Sciendo 2021
Materias:
Acceso en línea:https://doaj.org/article/e129ffa1f0f8468498cf304d0108d71e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!